Dr. Reddy's Laboratories Is in Talks to Enter Japan's Generic-Drug Market

Dr. Reddy’s Laboratories Ltd. is in talks to enter Japan’s generic-drug market, said S. Rajan, a company spokesman.

“We are in early stages of evaluating partnership options as part of our Japan entry strategy,” Rajan said in an e-mail today.

Dr. Reddy’s is in talks with three Japanese drugmakers to buy a stake, ET Now television channel reported yesterday, without saying where it got the information. The three companies are Towa Pharmaceutical Co., Sawai Pharmaceutical Co. and Fuji Pharma Co., the station said.

The Japanese companies denied the report in separate statements to the Tokyo Stock Exchange today.

To contact the reporter on this story: Adi Narayan in Mumbai at anarayan8@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.